利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.017 秒)

    Compositions and methods for modulating muscle cell and tissue contractility
    1.
    发明授权
    Compositions and methods for modulating muscle cell and tissue contractility 有权
    用于调节肌肉细胞和组织收缩力的组合物和方法

    公开(公告)号：US07425534B2

    公开(公告)日：2008-09-16

    申请号：US11019448

    申请日：2004-12-21

    申请人： Douglas B. Cines ,  Abd Al-Roof Higazi

    发明人： Douglas B. Cines ,  Abd Al-Roof Higazi

    IPC分类号： A61K38/48 ,  A61K38/00

    CPC分类号： A61K38/49 ,  C12N9/6462 ,  C12Y304/21073 ,  A61K2300/00

    摘要： The present invention relates to compositions and methods comprising one or more domains of urokinase-type plasminogen activator (uPA) in an amount effective to modulate one or more of the contractility and angiogenic activity of a mammalian muscle or endothelial cell or tissue for use in the treatment of a disease or condition having as a symptom thereof one or more of abnormal muscle cell or tissue contractility and abnormal angiogenic activity. The one or more domains of uPA can be present in the inventive compositions and methods either as part of the full uPA molecule in either single chain or two chain form (scuPA or tcuPA), or as an isolated polypeptide, or a fragment of the uPA molecule (e.g., the amino terminal fragment “ATF”), or a deletion mutant of the uPA molecule. The inventive methods comprise administering to a mammal afflicted with such a disease or condition the inventive composition, and modulating one or more of the contractility and the angiogenic activity of the muscle or endothelial cell or tissue, thereby treating the disease or condition. Kits for treating such diseases are also included.

    摘要翻译： 本发明涉及组合物和方法，其包含一种或多种尿激酶型纤溶酶原激活物结构域（uPA），其量有效调节哺乳动物肌肉或内皮细胞或组织的一种或多种收缩性和血管生成活性，以用于 治疗作为其症状的一种或多种异常肌细胞或组织收缩力和异常血管生成活性的疾病或病症。 uPA的一个或多个结构域可以存在于本发明的组合物和方法中，作为单链或两链形式（scuPA或tcuPA）中的完整uPA分子的一部分，或作为分离的多肽或uPA的片段 分子（例如，氨基末端片段“ATF”）或uPA分子的缺失突变体。 本发明的方法包括给患有这种疾病或疾病的哺乳动物施用本发明的组合物，并调节肌肉或内皮细胞或组织的一种或多种收缩性和血管生成活性，从而治疗疾病或病症。 也包括用于治疗这些疾病的药盒。

    Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy
    2.
    发明申请
    Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy 审中-公开
    用于调节尿激酶纤溶酶原激活物的肽和优化治疗功效的方法

    公开(公告)号：US20060069035A1

    公开(公告)日：2006-03-30

    申请号：US11210017

    申请日：2005-08-23

    申请人： Abd. Al-Roof Higazi

    发明人： Abd. Al-Roof Higazi

    IPC分类号： A61K38/08

    CPC分类号： A61K38/166 ,  A61K38/02 ,  A61K38/08 ,  A61K38/49 ,  A61K39/395 ,  A61K2300/00

    摘要： The present invention relates to compositions of the polypeptide EEIIMID and one or more fibrinolytic agents selected from the group consisting of scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative. The invention further relates to methods of enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic agents, or prolonging the half lives of the fibrinolytic agents by adding EEIIMD.

    摘要翻译： 本发明涉及多肽EEIIMID和一种或多种纤维蛋白溶解剂的组合物，其选自scuPA，tPA，uPA​​，tcuPA，链激酶，rt-PA，阿替普酶，rt-PA衍生物，替勃拉普酶，兰曲普酶，TNK-rt -PA，茴香酰化纤溶酶原链激酶复合物，anistreplase或链激酶衍生物。 本发明还涉及提高纤维蛋白溶解活性的方法，减少由纤维蛋白溶解剂引起的血管活性引起的副作用，或通过添加EEIIMD来延长纤维蛋白溶解剂的半衰期。

    Compositions and methods for modulating muscle cell and tissue contractility
    3.
    发明申请
    Compositions and methods for modulating muscle cell and tissue contractility 有权
    用于调节肌肉细胞和组织收缩力的组合物和方法

    公开(公告)号：US20050158300A1

    公开(公告)日：2005-07-21

    申请号：US11019448

    申请日：2004-12-21

    申请人： Douglas Cines ,  Abd Al-Roof Higazi

    发明人： Douglas Cines ,  Abd Al-Roof Higazi

    IPC分类号： A61K38/00 ,  A61K38/49 ,  C12N9/72 ,  C12Q1/68 ,  A61K38/48

    CPC分类号： A61K38/49 ,  C12N9/6462 ,  C12Y304/21073 ,  A61K2300/00

    摘要： The present invention relates to compositions and methods comprising one or more domains of urokinase-type plasminogen activator (UPA) in an amount effective to modulate one or more of the contractility and angiogenic activity of a mammalian muscle or endothelial cell or tissue for use in the treatment of a disease or condition having as a symptom thereof one or more of abnormal muscle cell or tissue contractility and abnormal angiogenic activity. The one or more domains of uPA can be present in the inventive compositions and methods either as part of the full uPA molecule in either single chain or two chain form (scuPA or tcuPA), or as an isolated polypeptide, or a fragment of the uPA molecule (e.g., the amino terminal fragment “ATF”), or a deletion mutant of the uPA molecule. The inventive methods comprise administering to a mammal afflicted with such a disease or condition the inventive composition, and modulating one or more of the contractility and the angiogenic activity of the muscle or endothelial cell or tissue, thereby treating the disease or condition. Kits for treating such diseases are also included.

    摘要翻译： 本发明涉及包含一种或多种尿激酶型纤溶酶原激活物结构域（UPA）的组合物和方法，其量有效调节哺乳动物肌肉或内皮细胞或组织的一种或多种收缩性和血管生成活性，以用于 治疗作为其症状的一种或多种异常肌细胞或组织收缩力和异常血管生成活性的疾病或病症。 uPA的一个或多个结构域可以存在于本发明的组合物和方法中，作为单链或两链形式（scuPA或tcuPA）中的完整uPA分子的一部分，或作为分离的多肽或uPA的片段 分子（例如，氨基末端片段“ATF”）或uPA分子的缺失突变体。 本发明的方法包括给患有这种疾病或疾病的哺乳动物施用本发明的组合物，并调节肌肉或内皮细胞或组织的一种或多种收缩性和血管生成活性，从而治疗疾病或病症。 也包括用于治疗这些疾病的药盒。

    Peptides derived from plasminogen activator inhibitor-1 and uses thereof
    6.
    发明授权
    Peptides derived from plasminogen activator inhibitor-1 and uses thereof 有权
    衍生自纤溶酶原激活物抑制剂-1的肽及其用途

    公开(公告)号：US08507436B2

    公开(公告)日：2013-08-13

    申请号：US12670099

    申请日：2008-07-24

    申请人： Abd Al-Roof Higazi

    发明人： Abd Al-Roof Higazi

    IPC分类号： A61K38/49

    CPC分类号： C07K14/8132 ,  A61K38/00

    摘要： The present invention relates to isolated 18-mer peptides corresponding to amino acid residues 369-386 of human plasminogen activator inhibitor 1 (PAI-1) and fragments thereof, compositions that include such peptides, and uses of such compositions for treating thromboembolic diseases and pathological conditions associated with neurological damage.

    摘要翻译： 本发明涉及对应于人纤溶酶原激活物抑制剂1（PAI-1）的氨基酸残基369-386及其片段的分离的18聚体肽，包括这些肽的组合物，以及这些组合物用于治疗血栓栓塞性疾病和病理学 与神经损伤相关的病症。

    Use of lipid conjugates in the treatment of disease
    9.
    发明授权
    Use of lipid conjugates in the treatment of disease 有权

    公开(公告)号：US07034006B2

    公开(公告)日：2006-04-25

    申请号：US09756765

    申请日：2001-01-10

    申请人： Saul Yedgar ,  David Shuseyov ,  Gershon Golomb ,  Reuven Reich ,  Isaac Ginsburg ,  Abd-al-Roof Higazi ,  Moshe Ligumski ,  Miron Krimsky ,  David Ojcius ,  Benito Antonio Yard ,  Fokko Johannes van der Woude ,  Edit Schnitzer

    发明人： Saul Yedgar ,  David Shuseyov ,  Gershon Golomb ,  Reuven Reich ,  Isaac Ginsburg ,  Abd-al-Roof Higazi ,  Moshe Ligumski ,  Miron Krimsky ,  David Ojcius ,  Benito Antonio Yard ,  Fokko Johannes van der Woude ,  Edit Schnitzer

    IPC分类号： A61K31/70 ,  A61K31/715 ,  C08B37/08 ,  C08B37/10 ,  C07H5/06

    CPC分类号： A61K47/544

    摘要： The invention provides novel methods for treating disease based upon the medicinal use of lipids and phospholipids covalently bound to physiologically acceptable monomers or polymers. Phosphatidylethanolamine moieties conjugated to physiologically acceptable monomers and polymers (PE conjugates) manifest an unexpectedly wide range of pharmacological effects, including stabilizing cell membranes; limiting oxidative damage to cell and blood components; limiting cell proliferation, cell extravasation and (tumor) cell migratory behavior; suppressing immune responses; and attenuating physiological reactions to stress, as expressed in elevated chemokine levels. The surprisingly manifold pharmacological properties of the PL-conjugates allow for the invention, disclosed herein, of novel methods for the treatment of a diverse range of disease states, including obstructive respiratory disease, including asthma; colitis and Crohn's disease; central nervous system insult, including blood brain barrier compromise, ischemic stroke, and multiple sclerosis; contact dermatitis; psoriasis; cardiovascular disease, including ischemic conditions and prophylaxis for invasive vascular procedures; cellular proliferative disorders, including anti-tumor vasculogenesis, invasiveness, and metastases; anti-oxidant therapy; hemolytic syndromes; sepsis; acute respiratory distress syndrome; tissue transplant rejection syndromes; autoimmune disease; viral infection; and hypersensitivity conjunctivitis. The therapeutic methods of the invention include administration of phosphatidylethanolamine bound to carboxymethylcellulose, heparin, hyaluronic acid, polyethylene glycol, and hemaccel. Disclosed herein are also new compounds comprised of phospholipid moieties bound to low molecular weight monomers and dimers, including mono- and disaccharides, carboxylated disaccharides, mono- and dicarboxylic acids, salicylates, bile acids, and fatty acids.

    Peptides for regulation of urokinase (uPA) and tissue type (tPA) plasminogen activator and method of optimizing therapeutic efficacy
    10.
    发明授权
    Peptides for regulation of urokinase (uPA) and tissue type (tPA) plasminogen activator and method of optimizing therapeutic efficacy 有权
    用于调节尿激酶（uPA）和组织型（tPA）纤溶酶原激活物的肽和优化治疗功效的方法

    公开(公告)号：US07271143B1

    公开(公告)日：2007-09-18

    申请号：US10386777

    申请日：2003-03-12

    申请人： Abd. Al-Roof Higazi

    发明人： Abd. Al-Roof Higazi

    IPC分类号： C07K1/00 ,  C07K5/00 ,  A61K38/00

    CPC分类号： C07K7/08 ,  A61K38/00 ,  C07K7/06 ,  Y10S514/834

    摘要： Compositions of the polypeptide SEQ ID NO:1, SEQ ID NO:2, anti-LRP antibodies, LRP antagonists, and/or one or more fibrinolytic agents are formulated for enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic agents, and/or prolonging the half lives of the fibrinolytic agents. The invention further relates to combination compositions and/or therapy regimens, comprising the polypeptide SEQ ID NO:1 and/or SEQ ID NO:2 and one or more currently used plasminogen activators.

    摘要翻译： 配制多肽SEQ ID NO：1，SEQ ID NO：2，抗-LRP抗体，LRP拮抗剂和/或一种或多种纤维蛋白溶解剂的组合物，用于增强纤维蛋白溶解活性，减少由于血管活性引起的副作用 纤维蛋白溶解剂，和/或延长纤维蛋白溶解剂的半衰期。 本发明还涉及组合组合物和/或治疗方案，其包含多肽SEQ ID NO：1和/或SEQ ID NO：2和一种或多种目前使用的纤溶酶原激活剂。